Published in J Med Chem on June 19, 2003
Implications for Management of PET Amyloid Classification Technology (IMPACT) | NCT02778971
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain (2008) 6.29
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol (2010) 6.17
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain (2008) 5.89
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol (2009) 4.55
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol (2012) 4.36
Molecular structure of β-amyloid fibrils in Alzheimer's disease brain tissue. Cell (2013) 4.02
Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci (2007) 3.91
Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol (2010) 3.64
Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol (2009) 3.60
Imaging amyloid deposition in Lewy body diseases. Neurology (2008) 3.09
Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med (2010) 2.77
Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol (2008) 2.62
CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat Neurosci (2013) 2.51
Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med (2009) 2.51
Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol (2010) 2.20
Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A (2003) 2.13
PET Imaging of Tau Deposition in the Aging Human Brain. Neuron (2016) 2.01
Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med (2009) 1.90
Brain amyloid and cognition in Lewy body diseases. Mov Disord (2012) 1.87
Relationships between β-amyloid and functional connectivity in different components of the default mode network in aging. Cereb Cortex (2011) 1.87
Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain (2010) 1.86
Relationship of dementia screening tests with biomarkers of Alzheimer's disease. Brain (2010) 1.80
Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults. J Neurosci (2012) 1.76
β-Amyloid affects frontal and posterior brain networks in normal aging. Neuroimage (2010) 1.68
Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol (2013) 1.68
Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease. Neuroimage (2007) 1.67
Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Arch Neurol (2012) 1.64
Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia (2011) 1.60
In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology (2010) 1.58
Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases. Neurology (2013) 1.53
Fluoro-pegylated (FPEG) imaging agents targeting Abeta aggregates. Bioconjug Chem (2007) 1.49
Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B. J Neurosci Methods (2008) 1.46
Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol (2012) 1.44
Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol (2011) 1.40
Cerebrovascular disease, β-amyloid, and cognition in aging. Neurobiol Aging (2011) 1.37
Biomarkers of Alzheimer's disease. Neurobiol Dis (2008) 1.37
Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology (2012) 1.33
Quick assembly of 1,4-diphenyltriazoles as probes targeting beta-amyloid aggregates in Alzheimer's disease. J Med Chem (2007) 1.30
F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain. J Med Chem (2005) 1.30
Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid. Alzheimers Dement (2011) 1.30
Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. Alzheimer Dis Assoc Disord (2008) 1.30
Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans. Neurobiol Aging (2010) 1.30
Molecular imaging of microglia/macrophages in the brain. Glia (2012) 1.29
18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective. J Med Chem (2010) 1.28
Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging study. Ann Neurol (2013) 1.27
Amyloid imaging of Lewy body-associated disorders. Mov Disord (2010) 1.27
Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med (2009) 1.27
Aβ Deposition in aging is associated with increases in brain activation during successful memory encoding. Cereb Cortex (2011) 1.26
The aging brain and cognition: contribution of vascular injury and aβ to mild cognitive dysfunction. JAMA Neurol (2013) 1.25
Partial volume correction in quantitative amyloid imaging. Neuroimage (2014) 1.24
The binding of thioflavin T and its neutral analog BTA-1 to protofibrils of the Alzheimer's disease Abeta(16-22) peptide probed by molecular dynamics simulations. J Mol Biol (2008) 1.22
A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.21
Characterization of IMPY as a potential imaging agent for beta-amyloid plaques in double transgenic PSAPP mice. Eur J Nucl Med Mol Imaging (2004) 1.21
Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS One (2013) 1.21
Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol Aging (2010) 1.19
[18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease. Eur J Nucl Med Mol Imaging (2013) 1.19
Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology. Eur J Nucl Med Mol Imaging (2012) 1.18
Small-animal PET imaging of amyloid-beta plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease. PLoS One (2012) 1.18
Covarying alterations in Aβ deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. Hum Brain Mapp (2012) 1.17
Coronary risk correlates with cerebral amyloid deposition. Neurobiol Aging (2011) 1.17
Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. Acta Neuropathol (2012) 1.16
Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. J Cell Mol Med (2008) 1.16
Cardiovascular risk factors, cortisol, and amyloid-β deposition in Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement (2012) 1.15
In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem (2008) 1.13
Role of family history for Alzheimer biomarker abnormalities in the adult children study. Arch Neurol (2011) 1.12
PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging (2005) 1.11
Insight into amyloid structure using chemical probes. Chem Biol Drug Des (2011) 1.10
Development of positron emission tomography β-amyloid plaque imaging agents. Semin Nucl Med (2012) 1.09
Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers. AIDS (2012) 1.09
Development and evaluation of compounds for imaging of beta-amyloid plaque by means of positron emission tomography. Eur J Nucl Med Mol Imaging (2008) 1.08
Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol (2014) 1.05
Associations between white matter hyperintensities and β amyloid on integrity of projection, association, and limbic fiber tracts measured with diffusion tensor MRI. PLoS One (2013) 1.03
Multiple Brain Markers are Linked to Age-Related Variation in Cognition. Cereb Cortex (2014) 1.02
Instrumental activities of daily living impairment is associated with increased amyloid burden. Dement Geriatr Cogn Disord (2011) 1.01
In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain. J Neurosci (2016) 1.00
Physical and structural basis for polymorphism in amyloid fibrils. Protein Sci (2014) 0.99
In vivo characterization of the early states of the amyloid-beta network. Brain (2013) 0.99
Unidirectional Influx and Net Accumulation of PIB. Open Neuroimag J (2008) 0.98
Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction. PLoS One (2013) 0.95
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv Pharmacol (2012) 0.94
CSF Biomarkers for Alzheimer's Disease Diagnosis. Int J Alzheimers Dis (2010) 0.94
Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J Nucl Med (2011) 0.94
BODIPY-based molecular probe for imaging of cerebral β-amyloid plaques. ACS Chem Neurosci (2012) 0.93
Diagnosis and biomarkers of predementia in Alzheimer's disease. BMC Med (2010) 0.93
Radionuclide labeling and evaluation of candidate radioligands for PET imaging of histone deacetylase in the brain. Bioorg Med Chem Lett (2013) 0.93
Frontotemporal network connectivity during memory encoding is increased with aging and disrupted by beta-amyloid. J Neurosci (2013) 0.92
Disclosure of amyloid imaging results to research participants: has the time come? Alzheimers Dement (2013) 0.91
Association of gray matter atrophy with age, β-amyloid, and cognition in aging. Cereb Cortex (2013) 0.91
Novel 5' untranslated region directed blockers of iron-regulatory protein-1 dependent amyloid precursor protein translation: implications for down syndrome and Alzheimer's disease. PLoS One (2013) 0.91
Analyzing thioflavin T binding to amyloid fibrils by an equilibrium microdialysis-based technique. PLoS One (2012) 0.91
Pd(II)-catalyzed ortho arylation of 2-arylbenzothiazoles with aryl iodides via benzothiazole-directed C-H activation. J Organomet Chem (2012) 0.91
Specific estrogen sulfotransferase (SULT1E1) substrates and molecular imaging probe candidates. Proc Natl Acad Sci U S A (2010) 0.90
Amyloid-β positron emission tomography imaging probes: a critical review. J Alzheimers Dis (2013) 0.90
Pharmacokinetics of [¹⁸F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 0.90
Synthesis and beta-amyloid binding properties of rhenium 2-phenylbenzothiazoles. Bioorg Med Chem Lett (2009) 0.90
Cortical binding of pittsburgh compound B, an endophenotype for genetic studies of Alzheimer's disease. Biol Psychiatry (2009) 0.89
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci (2005) 12.85
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64
Histone and chromatin cross-talk. Curr Opin Cell Biol (2003) 8.69
Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol (2008) 7.95
Molecular basis for the discrimination of repressive methyl-lysine marks in histone H3 by Polycomb and HP1 chromodomains. Genes Dev (2003) 7.91
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain (2007) 6.39
Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab (2005) 6.25
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain (2008) 5.89
PR-Set7 is a nucleosome-specific methyltransferase that modifies lysine 20 of histone H4 and is associated with silent chromatin. Mol Cell (2002) 5.59
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med (2005) 5.10
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
Binary switches and modification cassettes in histone biology and beyond. Nature (2003) 4.75
PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J Exp Med (2010) 4.74
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 4.38
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol (2007) 4.11
Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol (2007) 3.83
Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol (2002) 3.12
The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. Am J Psychiatry (2013) 3.06
The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 2.86
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2011) 2.75
Hgc1, a novel hypha-specific G1 cyclin-related protein regulates Candida albicans hyphal morphogenesis. EMBO J (2004) 2.72
Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol (2009) 2.66
Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci (2008) 2.57
Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol (2009) 2.42
Statins enhance formation of phagocyte extracellular traps. Cell Host Microbe (2010) 2.28
Regulation of p53 target gene expression by peptidylarginine deiminase 4. Mol Cell Biol (2008) 2.27
Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci (2005) 2.17
Peptidylarginine deiminase 4 contributes to tumor necrosis factor α-induced inflammatory arthritis. Arthritis Rheumatol (2014) 2.14
Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A (2003) 2.13
The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci (2003) 2.06
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med (2012) 2.00
Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc Natl Acad Sci U S A (2013) 1.98
The RING finger protein MSL2 in the MOF complex is an E3 ubiquitin ligase for H2B K34 and is involved in crosstalk with H3 K4 and K79 methylation. Mol Cell (2011) 1.96
Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest (2005) 1.94
Histone Arg modifications and p53 regulate the expression of OKL38, a mediator of apoptosis. J Biol Chem (2008) 1.93
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) (2012) 1.90
Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci (2009) 1.89
Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry (2009) 1.85
A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett (2002) 1.79
Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease. Neuroimage (2007) 1.67
Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. Neuroimage (2006) 1.65
In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers. Angew Chem Int Ed Engl (2005) 1.60
Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage (2007) 1.53
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci (2011) 1.51
Imaging of CNS myelin by positron-emission tomography. Proc Natl Acad Sci U S A (2006) 1.49
The enhancement of histone H4 and H2A serine 1 phosphorylation during mitosis and S-phase is evolutionarily conserved. Chromosoma (2004) 1.47
Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B. J Neurosci Methods (2008) 1.46
Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity. J Biol Chem (2012) 1.45
In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol (2011) 1.40
Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.37
PAD4 mediated histone hypercitrullination induces heterochromatin decondensation and chromatin unfolding to form neutrophil extracellular trap-like structures. Front Immunol (2012) 1.37
Structural and histone binding ability characterizations of human PWWP domains. PLoS One (2011) 1.32
11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. J Nucl Med (2006) 1.32
Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. Neurobiol Aging (2008) 1.31
Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. Alzheimer Dis Assoc Disord (2008) 1.30
Dynamic alterations of specific histone modifications during early murine development. J Cell Sci (2004) 1.30
Progression of cerebral amyloid load is associated with the apolipoprotein E ε4 genotype in Alzheimer's disease. Biol Psychiatry (2010) 1.29
Regulation of histone H2A and H2B deubiquitination and Xenopus development by USP12 and USP46. J Biol Chem (2010) 1.28
Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med (2009) 1.27
X-34 labeling of abnormal protein aggregates during the progression of Alzheimer's disease. Methods Enzymol (2006) 1.25
VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice. Blood (2013) 1.24
Longitudinal cerebral blood flow and amyloid deposition: an emerging pattern? J Nucl Med (2008) 1.22
Peptidylarginine deiminases in citrullination, gene regulation, health and pathogenesis. Biochim Biophys Acta (2013) 1.20
Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol (2007) 1.19
A novel fluorescent probe that is brain permeable and selectively binds to myelin. J Histochem Cytochem (2006) 1.19
Pulse wave velocity is associated with β-amyloid deposition in the brains of very elderly adults. Neurology (2013) 1.18
Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Arch Neurol (2005) 1.18
Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. Neuroimage (2013) 1.17
In vivo assessment of amyloid-β deposition in nondemented very elderly subjects. Ann Neurol (2013) 1.17
Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. Acta Neuropathol (2012) 1.16
Imaging amyloid-beta deposits in vivo. J Cereb Blood Flow Metab (2002) 1.15
18F-FPEB, a PET radiopharmaceutical for quantifying metabotropic glutamate 5 receptors: a first-in-human study of radiochemical safety, biokinetics, and radiation dosimetry. J Nucl Med (2013) 1.15
Molecular probes for imaging myelinated white matter in CNS. J Med Chem (2008) 1.14
Amyloid burden and neural function in people at risk for Alzheimer's Disease. Neurobiol Aging (2013) 1.14
Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol (2009) 1.14
Amyloid imaging: from benchtop to bedside. Curr Top Dev Biol (2005) 1.13